Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 Receptor Signaling in Glucagon-stimulated Insulin Secretion
NCT04459338Phase 3Completed
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of exendin 9-39 in type 2 diabetes mellitus (T2DM), obesity. Started Mar 2021; status: completed.
02
Drugs
exendin 9-39
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04459338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459338.